Aligning MML with the ever-growing CE Innovation ecosystems.

This week, MedTech Makers Lab had the opportunity to deliver a workshop with INOVIA and Ynovate focused on one of the biggest challenges facing European innovation ecosystems today: moving from “supporting startups” to actually commercialising them.

INOVIA has rapidly become an important innovation hub within the Žilina region of Slovakia, supporting startups, SMEs, researchers, and regional innovation programmes while helping build a stronger technology and entrepreneurial ecosystem across the region. Their work connects companies, universities, investors, and public sector stakeholders to strengthen innovation capacity and regional competitiveness.

Ynovate, meanwhile, has grown into one of Central Europe’s most connected innovation networks, bringing together innovation centres and agencies across the Czech Republic and Slovakia. Through its shared expert network, investor access, mentoring ecosystem, and regional collaboration model, Ynovate creates cross-border opportunities for founders and innovation-led companies.

Across Europe, incubators and accelerators are producing exceptional deeptech, medtech, AI, and life sciences innovation — but too many programmes still stop at mentorship, grant support, or pitch preparation. Founders often leave acceleration programmes without regulatory pathways, commercial infrastructure, investment readiness, clinical validation strategies, or international market access.

This is where MedTech Makers Lab (MML) is designed to operate differently.

MML acts as a commercialisation extension to accelerators, incubators, universities, and regional innovation ecosystems. We plug directly into existing programmes to help founders transition from research and prototype stages into scalable venture-backed businesses. Our model combines venture building, regulatory strategy, cross-border market access, investment structuring, operational execution, and long-term enterprise development.

What makes this particularly relevant for European ecosystems is the combination of UK venture capital and investment experience with emerging European innovation. The UK remains one of the most mature venture markets in Europe, particularly across medtech, life sciences, and deeptech. Through MML’s growing pan-European footprint, we are now creating bridges between UK capital markets and high-potential innovation ecosystems across Central and Eastern Europe, Southern Europe, and emerging regional hubs.

The opportunity ahead is significant:

• European ecosystems have world-class research capability

• Many regions still lack structured commercialisation infrastructure

• Founders need long-term execution partners, not just short-term programmes

• Investors are increasingly looking cross-border for undervalued innovation opportunities

• Cross-regional collaboration is becoming essential for scaling innovation internationally

MML is positioning itself as a pan-European venture building and commercialisation platform — helping ecosystems move beyond “innovation theatre” and into sustainable company creation, international scaling, and real economic development.

Thank you again to INOVIA and Ynovate for the collaboration and the open discussion around how Europe can build stronger, more execution-focused innovation ecosystems together.